Fraser Wright - Spark Therapeutics Insider

272 -- Germany Stock  

EUR 47.08  0.94  1.96%

Dr. J. Fraser Wright Ph.D. is CoFounder and Chief Technology Officer of Spark Therapeutics Inc. From July 2013 until he joined Spark Dr. Wright served as our Chief Technology Advisor. Dr. Wright established and had been the director of the Clinical Vector Core Laboratory at CHOP from 2004 to January 2015. Dr. Wright also was a Professor at the Perelman School of Medicine at the University of Pennsylvania. Dr. Wright previously served as Director of Development and Clinical Manufacturing at Avigen Inc. from 1999 to 2004 and as scientist with Sanofi Pasteur and as scholar investigator with the Canadian blood services
Age: 56  Founder Since 2015  Ph.D    
Wright received his B.S. and Ph.D. in biochemistry from the University of Toronto.

Management Efficiency

The company has return on total asset (ROA) of (28.14) % which means that it has lost $28.14 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (64.37) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 35.75 M in total debt with debt to equity ratio (D/E) of 7.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Spark Therapeutics has Current Ratio of 11.13 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Entity Summary

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. Spark Therapeutics operates under Biotechnology classification in Germany and traded on Frankfurt Stock Exchange. It employs 315 people.Spark Therapeutics (272) is traded on Frankfurt Stock Exchange in Germany. It is located in 3737 Market Street and employs 315 people.

Spark Therapeutics Leadership Team

Romuald Corbau, Translational Research Lead
Carol GrevePhilips, Head of Business Development and Strategy
Robert Perez, Director
Lars Ekman, Independent Director
Jennifer Wellman, Co-Founder and Head of Regulatory Strategy
Fraser Wright, Co-Founder and CTO
Lorris Betz, Director
Morgan Molloy, Head of U.S. Commercial
Joseph Barge, General Counsel and Head of Business Administration
Katherine High, President Chief Scientific Officer, Director
Elliot Sigal, Independent Director
John Furey, COO
Vincent Milano, Independent Director
Lota Zoth, Director
Rogerio Coelho, Chief Commercial Officer
Guang Qu, Head of Process Development
Daniel Takefman, Head of Regulatory Affairs
Stephen Webster, CFO
Rogerio Vivaldi, Chief Commercial Officer
Diane Blumenthal, Head of Technical Operations
Jeffrey Marrazzo, CEO, Co-Founder, Director
Daniel Faga, Chief Business Officer
Anand Mehra, Independent Director
Linda Hearne, Financial Operations and Analysis Lead
Paul Gil, Regulatory CMC and Quality Assurance Lead
Charles Sigal, Independent Director
Federico Mingozzi, Chief Scientific Officer
Steven Altschuler, Independent Chairman of the Board
Lisa Dalton, Head - Human Resources

Stock Performance Indicators

Did you try this?

Run CEO Directory Now


CEO Directory

Screen CEOs from public companies around the world
All  Next Launch CEO Directory

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Thematic Ideas
Explore Investing Ideas  
Check also Trending Equities. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.